Norgine   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Amsterdam Netherlands (1906)

Organization Overview

First Clinical Trial
2000
NCT00404040
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Norgine | Norgine BV | Norgine Ltd | Norgine Pharmaceuticals Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ascites (Phase 4)

Brain Diseases (Phase 4)

Breast Neoplasms (Phase 4)

Colonic Neoplasms (Phase 3)

Colorectal Neoplasms (Phase 4)

Constipation (Phase 4)

Digestive System Diseases (Phase 4)

Esophagitis, Peptic (Phase 3)

Fatty Liver (Phase 2)

Fecal Impaction (Phase 2)

Fecal Incontinence (Phase 2)

Fibrosis (Phase 4)

Gastroesophageal Reflux (Phase 3)

Gastrointestinal Diseases (Phase 4)

Heartburn (Phase 3)

Hepatic Encephalopathy (Phase 4)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis, Viral, Human (Phase 2)

Hypertension, Portal (Phase 4)

Irritable Bowel Syndrome (Phase 4)

Liver Cirrhosis (Phase 4)

Liver Diseases (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 2)

Pathologic Processes (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 67
  • # of Trial APIs: 37